We are live on ! Find out more
NVS icon

Novartis

909 hedge funds and large institutions have $19.9B invested in Novartis in 2017 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 342 increasing their positions, 335 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 61

9% more capital invested

Capital invested by funds: $18.3B → $19.9B (+$1.61B)

2% more repeat investments, than reductions

Existing positions increased: 342 | Existing positions reduced: 335

0.71% more ownership

Funds ownership: 10.65%11.36% (+0.71%)

1% more funds holding

Funds holding: 904909 (+5)

5% less funds holding in top 10

Funds holding in top 10: 2120 (-1)

55% less call options, than puts

Call options by funds: $30.9M | Put options by funds: $68.2M

Holders
909
Holders Change
+5
Holders Change %
+0.55%
% of All Funds
22.63%
Holding in Top 10
20
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.76%
% of All Funds
0.5%
New
76
Increased
342
Reduced
335
Closed
61
Calls
$30.9M
Puts
$68.2M
Net Calls
-$37.3M
Net Calls Change
-$54.7M
Name Holding Trade Value Shares
Change
Change in
Stake
RJA
26
Raymond James & Associates
Florida
$133M +$16.7M +250,957 +14%
JHIU
27
Janus Henderson Investors US
Colorado
$131M +$130M +1,958,263 +34,404%
FWIA
28
Fort Washington Investment Advisors
Ohio
$124M +$2.51M +37,741 +2%
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$122M +$10.2M +153,387 +9%
Boston Partners
30
Boston Partners
Massachusetts
$119M +$3.6M +54,087 +3%
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$118M +$27.9M +418,976 +31%
Lazard Asset Management
32
Lazard Asset Management
New York
$115M -$47.6M -714,631 -29%
Fayez Sarofim & Co
33
Fayez Sarofim & Co
Texas
$110M -$1.26M -18,971 -1%
Capital International Investors
34
Capital International Investors
California
$109M
PPA
35
Parametric Portfolio Associates
Washington
$108M +$12.3M +184,862 +13%
Millennium Management
36
Millennium Management
New York
$102M +$102M +1,535,237 New
CAM
37
CGOV Asset Management
Ontario, Canada
$98.7M +$1.82M +27,264 +3%
Arrowstreet Capital
38
Arrowstreet Capital
Massachusetts
$98.6M +$98.7M +1,481,634 New
Ameriprise
39
Ameriprise
Minnesota
$89.8M -$14.4M -215,474 -14%
SEI Investments
40
SEI Investments
Pennsylvania
$82.9M +$6.51M +97,649 +9%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$80.1M -$4.83M -72,476 -6%
RFS
42
Rockefeller Financial Services
New York
$79M -$638K -9,572 -0.8%
JWBC
43
John W. Bristol & Co
New York
$78.7M +$16.5M +246,915 +26%
Natixis Advisors
44
Natixis Advisors
Massachusetts
$77.8M +$7.22M +108,304 +10%
EAM
45
Edge Asset Management
Washington
$76M +$7.46K +112 +0%
Macquarie Group
46
Macquarie Group
Australia
$74M +$1.22M +18,236 +2%
USSCPF
47
United States Steel & Carnegie Pension Fund
New York
$73.8M -$10M -150,771 -12%
SI
48
Scharf Investments
California
$73.6M -$3.23M -48,506 -4%
SCM
49
Sterling Capital Management
North Carolina
$71.5M -$8.06M -120,924 -10%
Goldman Sachs
50
Goldman Sachs
New York
$71.2M -$4.79M -71,901 -6%

NVS Hedge Fund Activity: Q1 2017 in Review

909 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2017, worth a combined $19.9B — up 8.8% from $18.3B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new NVS positions and 61 closed out — a net gain of 15 holders — while 342 added to existing stakes and 335 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $362M. The largest seller was 1832 Asset Management, cutting an estimated $239M.

  • 909 institutional investors held Novartis (NVS) as of Q1 2017, up from 904 in Q4 2016.
  • Funds reported $19.9B of Novartis stock for Q1 2017, up 8.8% quarter-over-quarter.
  • 76 funds opened new Novartis positions in Q1 2017 and 61 closed out, a net change of +15 holders.
  • The largest Novartis buyer in Q1 2017 was Dodge & Cox, an estimated $362M added.
  • The largest Novartis seller in Q1 2017 was 1832 Asset Management, an estimated $239M sold.

Based on aggregated 13F filings for Q1 2017.